Cardiovascular risk assessments in chronic myeloid leukemia allow identification of patients at high risk of cardiovascular events during treatment with nilotinib

Am J Hematol. 2015 May;90(5):E100-1. doi: 10.1002/ajh.23976.
No abstract available

Publication types

  • Letter

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Agents / therapeutic use*
  • Cardiovascular Diseases / complications*
  • Cardiovascular Diseases / pathology
  • Cardiovascular Diseases / prevention & control
  • Female
  • Humans
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / complications*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology
  • Male
  • Middle Aged
  • Patient Selection
  • Pyrimidines / therapeutic use*
  • Retrospective Studies
  • Risk Factors

Substances

  • Antineoplastic Agents
  • Pyrimidines
  • nilotinib